Bellicum Reports Clinical Results of BPX-501, Showed A Disease Relapse Rate of 14.72%, Non-Relapse Mortality of 3.23% In BPX-501 Patients; Company Says Results Compare Favorably To Historic Controls
Paul Quintaro